FGF R4

FGF R4 Overview

English NameFibroblast growth factor receptor 4Approved Drugs3
Drugs in Clinical Trials19Target SynonymCD334 Antigen,EC 2.7.10.1,FGFR-4,Receptor, Fibroblast Growth Factor, Type 4,EC 2.7.10,JTK2,Tyrosine Kinase Related To Fibroblast Growth Factor Receptor,Hydroxyaryl-Protein Kinase,Tyrosylprotein Kinase,EC:2.7.10.1,Fibroblast growth factor receptor 4,CD334,FGFR4,TKF
Highest Development StageApproved
English NameFibroblast growth factor receptor 4
Target SynonymCD334 Antigen,EC 2.7.10.1,FGFR-4,Receptor, Fibroblast Growth Factor, Type 4,EC 2.7.10,JTK2,Tyrosine Kinase Related To Fibroblast Growth Factor Receptor,Hydroxyaryl-Protein Kinase,Tyrosylprotein Kinase,EC:2.7.10.1,Fibroblast growth factor receptor 4,CD334,FGFR4,TKF
Approved Drugs3
Drugs in Clinical Trials19
Highest Development StageApproved

FGF R4 Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Human (2)

  • Tag

    His Tag (1)Fc Tag (1)

  • Conjugate

    Unconjugated (2)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
FG4-H5228
Human
HEK293
Human FGF R4 / CD334 Protein, His Tag, low endotoxin
FG4-H5253
Human
HEK293
Human FGF R4 / CD334 Protein, Fc Tag (MALS & SPR verified)
Total: 2
  • 1

FGF R4 Background

Fibroblast growth factor receptor 4(FGFR4) is also known as CD334, JTK2, hydroxyaryl-protein kinase, TKF, protein-tyrosine kinase . The FGFR4 gene provides instructions for making a protein called fibroblast growth factor receptor 4. This protein is part of a family of fibroblast growth factor receptors that share similar structures and functions. These receptor proteins play a role in important processes such as cell division, regulating cell growth and maturation, formation of blood vessels, wound healing, and embryo development.The FGFR4 protein interacts with specific growth factors to conduct signals from the environment outside the cell to the nucleus. The nucleus responds to these signals by switching on or off appropriate genes that help the cell adjust to changes in the environment. In response, the cell might divide, move, or mature to take on specialized functions. Although specific functions of FGFR4 remain unclear, studies indicate that the gene is involved in muscle development and the maturation of bone cells in the skull. The FGFR4 gene may also play a role in the development and maintenance of specialized cells (called foveal cones) in the light-sensitive layer (the retina) at the back of the eye.

FGF R4 Synonyms

FGFR4,CD334,JTK2,MGC20292,TKF

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
SC-0011SC-0011Phase 3 ClinicalShijiazhuang Zhikang Hongren New Drug Development Co LtdCarcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms
Details
AUR-109ODM-203; AUR-109Phase 2 ClinicalOrion CorpBreast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pulmonary Fibrosis; Solid tumours; Urinary Bladder Neoplasms
Details
RogaratinibBAY-1163877Phase 2 ClinicalBayer AGBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Neoplasms; Sarcoma; Solid tumours; Urinary Bladder Neoplasms
Details
FisogatinibBLU-554; CS-3008Phase 2 ClinicalBlueprint Medicines CorpCarcinoma, Hepatocellular
Details
BB-102BB-102; BB102Phase 2 ClinicalBroadenbio Co LtdCarcinoma, Hepatocellular; Solid tumours
Details
GunagratinibICP-192Phase 2 ClinicalBeijing Tiancheng Pharmaceutical Technology Co LtdBiliary Tract Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Head and Neck Neoplasms; Lung Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
IrpagratinibABSK-011Phase 2 ClinicalABbisko Therapeutics Co LtdCarcinoma, Hepatocellular; Liver Neoplasms; Solid tumours
Details
BPI-43487BPI-43487Phase 1 ClinicalBetta Pharmaceuticals Co LtdBiliary Tract Neoplasms; Carcinoma, Hepatocellular; Solid tumours
Details
HS-236HS-236Phase 1 ClinicalZhejiang Hisun Pharmaceutical Co LtdSolid tumours
Details
HS-10340HS-10340Phase 1 ClinicalChangzhou Hengbang Pharmaceutical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co LtdSolid tumours
Details
ICP-105ICP-105Phase 1 ClinicalBeijing Innocare Pharma Tech Co Ltd, Beijing Tiancheng Pharmaceutical Technology Co Ltd, Nanjing Tianyin Jianhua Pharmaceutical Technology Co LtdLiver Neoplasms; Solid tumours
Details
ZSP-1241ZSP-1241Phase 1 ClinicalGuangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co LtdBiliary Tract Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Stomach Neoplasms
Details
H3B-6527H3B-6527Phase 1 ClinicalH3 Biomedicine IncCarcinoma, Hepatocellular; Liver Neoplasms
Details
FGFR4-CAR T Cells Therapy(National Cancer Institute)Phase 1 ClinicalNational Cancer InstituteRhabdomyosarcoma
Details
TYRA-430TYRA-430Phase 1 ClinicalTyra Biosciences IncCarcinoma, Hepatocellular; Neoplasms; Solid tumours
Details
SYHX-2005SYHX-2005; SYHX2005Phase 1 ClinicalCspc Ouyi Pharmaceutical Co LtdSolid tumours
Details
JAB-6343Phase 1 ClinicalJacobio Pharmaceuticals Co LtdSolid tumours
Details
SY-4798SY-4798Phase 1 ClinicalShouyao Holding (Beijing) Co LtdBiliary Tract Neoplasms; Carcinoma, Hepatocellular; Solid tumours
Details
ABSK-012ABSK-012; ABSK012Phase 1 ClinicalABbisko Therapeutics Co LtdSolid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Lenvatinib MesilateE-7080; MK-7902; ER-203492-00ApprovedEisai Co LtdKisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛United StatesThyroid NeoplasmsEisai Inc2015-02-13Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Follicular; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Hepatic Insufficiency; Liver Diseases; Liver Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Paraganglioma; Pheochromocytoma; Renal Insufficiency; Solid tumours; Stomach Neoplasms; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Uterine Cervical Neoplasms
Details
FutibatinibTAS-120ApprovedOtsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co LtdLYTGOBIUnited StatesCholangiocarcinomaTaiho Oncology Inc2022-09-30Biliary Tract Neoplasms; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Lymphoma; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms
Details
Erdafitinib890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210ApprovedAstex Pharmaceuticals IncBalversa, 博珂United StatesCarcinoma, Transitional CellJanssen Biotech Inc2019-04-12Adenocarcinoma; Bile Duct Neoplasms; Bone metastases; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Ependymoma; Esophageal Neoplasms; Glioma; Hepatic Insufficiency; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Medulloblastoma; Metastatic breast cancer; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Wilms Tumor; Xanthogranuloma, Juvenile
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland